Literature DB >> 11933271

Myxopapillary ependymoma: cytomorphologic characteristics and differential diagnosis.

Peter Kulesza1, Tarik Tihan, Syed Z Ali.   

Abstract

Myxopapillary ependymoma (ME) is a rare tumor with a predilection for sacrococcygeal area of adults. We present the cytomorphology of one such case in a 21-yr-old man, diagnosed by fine-needle aspiration (FNA). The tumor disclosed biphasic morphology with nests and aggregates of epithelioid malignant cells as well as branching cords of myxohyaline material. Most noticeable was the presence of distinct hyaline globules surrounded by neoplastic cells. The differential diagnosis of ME includes chordoma, adenoid cystic carcinoma, mucinous adenocarcinoma, and germ cell tumor. An accurate preoperative diagnosis of ME on FNA can be achieved based on its distinctive cytomorphologic features. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11933271     DOI: 10.1002/dc.10086

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  4 in total

1.  Immunohistochemical study of CD99 and EMA expression in ependymomas.

Authors:  Soheir Mahfouz; Ahmad Abdel Aziz; Samia M Gabal; Samar el-Sheikh
Journal:  Medscape J Med       Date:  2008-02-19

2.  Myxopapillary ependymoma: Lesser known cytomorphologic features.

Authors:  Monisha Choudhury; Archna Rautela; Manupriya Nain
Journal:  J Cytol       Date:  2015 Jan-Mar       Impact factor: 1.000

3.  Teaching Case 2-2018: Sclerosing myxopapillary ependymoma mimicking whorling-sclerosing meningioma.

Authors:  Julia Lang; Thomas Czech; Irene Slavc; Dominik Reisinger; Sophie Bartsch; Johannes A Hainfellner; Christine Haberler; Ellen Gelpi
Journal:  Clin Neuropathol       Date:  2018 Mar/Apr       Impact factor: 1.368

4.  Osteolytic myxopapillary ependymoma with marked hyaline degeneration in a 72-year-old male: A case report.

Authors:  Hai Wang; Zhiyuan Zhang; Mohammad Shahidul Makki; Qunli Shi
Journal:  Oncol Lett       Date:  2013-06-14       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.